Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nevada Medical Cannabis Patient Growth Bounces Back
March 17, 2017 at 11:43 am
Exclusive article by Alan Brochstein, CFA
After a two month pause in growth following the November elections, Nevada medical cannabis patient growth jumped by 4.1% in February to 26,519. This follows 0.3% growth in December and 0.4% growth in January, the slowest rates since the 0.2% monthly growth in in June 2015.
Year-over-year growth of 74% is still beneath the triple-digit growth rates from June to October but remains robust. We reached out to Leslie Bocskor of Electrum Partners for some insight, and he suggested several factors that may explain the pause in December and January, including confusion over the timing of legalization, potential streamlining of the process for medical recommendations and improvements in the supply of medical cannabis recently.
The full report from the Nevada Department of Health and Human Services’ Division of Public and Behavioral Health, which also breaks down the cardholders by age and medical condition, can be found here. Severe pain represents the most common qualifying condition at over 84%, followed by muscle spasms, at 12.5%. 0.2% of card-holders are under 18 and are excluded from this data, which compares the cardholders to the overall Nevada adult population based on 2010 census data. Similar to what we reported as of November 2015, the patient population tends to be older than the overall Nevada population, with 39.1% of the cardholders 55 or older compared to 31.4% of the adult population. Those between 18 and 24 represent 12.1% of the adult population but just 6.2% of the cardholders.
Good for you.
Enjoy the profits!
When do think the buyout will be announced?
Like a settling of sorts for earlier trades.
I wasn't sure if OTC did it the same way as the big exchanges.
OTC,
I'm in it for a long time. The laws have finally changed enough for CBIS to get things moving here and a few cannabis patents won't hurt either!
Some big pharma will be looking to swallow CBIS up for the pipeline.
Looks like an uptick, too.
Oh...Ok...and you said "and that medical guy ..wtf is he thinking goimg along with dabneys lies"
That's a good question!
As a matter of fact, Dana/Farber is working with CBIS right now as I write this!
How many people and entities do you suppose would go along with a "fake" company?
There is too much evidence that what they are doing is real and there is much evidence that cannabis is a miracle plant that has yet to be proven out in credible studies that our company is conducting now.
Case closed!
sicofbs,
I saw where CBIS paid $201,000 for the collaboration with Dana/Farber Cancer Institute, right?
Do you think $201,000 is just "play money" or what?
This is a serious collaboration which will produce serious results for the company!
You won't convince me of anything less!
FinancialBuzz.com: The Growth of Legal Cannabis Markets and Tax Revenues
NEWS PROVIDED BY
FinancialBuzz.com
Mar 10, 2017, 09:00 ET
SHARE THIS ARTICLE
NEW YORK, March 10, 2017 /PRNewswire/ --
The U.S. could see significant economic benefits from the expanding legal cannabis markets. According to the Cannabis Industry Annual Report published by New Frontier Data, the legal cannabis market is projected to reach $24.1 billion by 2025 and could generate $2.3 billion in state tax revenue from retail sales by the year 2020. The estimate is based on the assumption that the number of legal states remains the same and all states continue their projected growth. As the pace of cannabis legalization in the United States accelerated in recent years, the legal cannabis market could become a major driver for the economy. Endexx Corporation (OTC: EDXC), Cannabis Science Inc. (OTC: CBIS), Hemp Inc. (OTC: HEMP), Surna Inc. (OTC: SRNA), Mountain High Acquisitions Corp. (OTC: MYHI)
New Frontier Data, CEO, Giadha Aguirre De Carcer said: "During this tough economy, states are looking for any way to close their budget shortfalls and it appears that cannabis may hold an answer for them. New Frontier Data looked at the potential revenues that could be generated from state cannabis taxes and found that in this year alone, states could raise nearly $750 million and triple that number by 2020. These revenues will have a meaningful impact on state programs and provide governors with much needed breathing room in their budgets."
http://www.prnewswire.com/news-releases/financialbuzzcom-the-growth-of-legal-cannabis-markets-and-tax-revenues-615873183.html
Where can I see the news?
So if they wanted to buy at .30 a share it would cost them about $700,000,000
I don't think this is even close to happening.
Why lie?
This character, otc1investor, is posting that garbage on different stock message boards. He's a little story teller.
Here's what would be the ultimate cannabis unchaining...
“I’m more hopeful than ever before that we can move legislation like the Regulate Marijuana Like Alcohol Act,” Polis said, referencing legislation introduced in 2015 to remove marijuana entirely from the Controlled Substances Act, decriminalize the substance and open the doors to a nationally regulated recreational industry under the oversight of the federal Bureau of Alcohol, Tobacco, Firearms and Explosives."
http://www.thecannabist.co/2017/02/06/congress-marijuana-legislation-cannabis-caucus/72897/
Crown Baus Capital Corporation announces the Company had acquired a 100-acre investment participation in the Cannabis Science Inc. (OTC: CBIS) Property and Drug Development Projects spread across California and Nevada. In this agreement, it includes cultivation, laboratory, and manufacturing capabilities. "I am excited to announce our agreement with CBIS. That's 66,000 sq. ft. we will be building out with CBIS & CBCA over this spring and summer. We are certainly looking to bring that number well over 100,000 sq. ft. over the coming months. In line with CBCA's growth strategy in one of our core areas, we see tremendous value in our Property and Drug Development Projects. Each one-acre parcel provides investors with 33,000 square feet of space to build fully-licensed and state compliant medical cannabis and/or industrial hemp production facilities," said President and Chief Executive Officer of both Crown Baus Capital and Cannabis Science, Raymond C. Dabney.
http://www.nbcrightnow.com/story/34583741/cannabis-products-are-becoming-more-acceptable
Spicer telegraphed the administration won’t take a get-tough approach against medical marijuana, saying Trump believes in its ability to "comfort" people suffering from debilitating diseases.
http://thehill.com/homenews/administration/320902-white-house-hints-at-crackdown-on-recreational-marijuana
June of 2016 - Old news
Qualcomm Faces $900 Million Fine from Korea
Peter Clarke
7/20/2016 03:24 PM EDT
Post a comment
NO RATINGS
LOGIN TO RATE
inShare
18
LONDON—South Korea's Fair Trade Commission (FTC) has said that semiconductor and telecoms company Qualcomm is facing a fine of up to 1 trillion won (about $875 million) for allegedly violating antitrust regulations, according to a Korea Times report .
This comes some 17 months after Qualcomm was ordered to pay a $975 million fine to the Chinese authorities to settle an antitrust case there and also granted improved terms to access Qualcomm's extensive portfolio of patents essential to 3G/4G cellular communications.
The South Korean FTC's investigation started at about the same time as China's was finishing.
"Qualcomm's business model is still controversial because it charges excessively high licensing fees and requires unfair conditions for use of its patents," the Korea Times report quoted an FTC official saying. He also said the antitrust agency will take steps to stop Qualcomm taking advantage of its dominant position.
It appears that the FTC has already decided on the verdict but it will set the final fine after reviewing a response from Qualcomm. The announcement could come as soon as this week, according to another report.
One of the things Qualcomm has insisted on in the past is that chip purchasers pay a patent royalties based in equipment pricing rather than on chip pricing. During its findings against Qualcomm China struck a deal that knocked about a third of the cost of such licensing while licensees elsewhere pay at the original rate (see China Deal Squeezes Royalty Cuts from Qualcomm ).
"Qualcomm has been collecting royalty fees from mobile phone manufacturers based on certain fixed rates from the suggested price of a mobile device. Qualcomm should have sought royalty fees based on each chipset," the report quoted an FTC official saying.
Qualcomm is collecting about $1.27 billion in royalty fees annually from Korean consumer electronics manufacturers such as Samsung and LG Electronics.
—Peter Clarke covers business news and analog for EE Times Europe.
http://www.marketwatch.com/story/sk3-groups-otc-pink-skto-medical-greens-is-pleased-to-announce-that-the-first-bottles-of-dharmanoltm-are-shipping-and-will-be-immediately-available-on-wwwpharmajanescom-among-other-places-2014-02-14
press release
Feb. 14, 2014, 10:50 a.m. EST
LOS ANGELES, CA, Feb 14, 2014 (Marketwired via COMTEX) -- SK3 Group, Inc's (otc pink:SKTO) subsidiary Medical Greens is pleased to announce that the first bottles of Dharmanol(TM) Whole Plant tablets, for which Medical Greens has the exclusive license, are shipping today. Dharmanol(TM) is a medical cannabis-based supplement that contains all of the natural elements of the cannabis/hemp plant that are thought to promote healing, with the exception of THC, the molecule which is responsible for the psychoactive effect -- or "high" -- of marijuana.
Dharmanol(TM), developed by David Hoye and Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories, contains under .03% THC, less than many hemp-based health products that are sold at stores such as Costco and Walgreens. But it contains 10 mg. of the non-psychoactive phyto-cannabinoids that are present in hemp/cannabis, and are thought to contribute to the myriad of mechanisms that many university-level scientific studies have shown to be responsible for the remarkable healing power of medical marijuana.
Dharmanol(TM) tablets will be available soon in California through AEGY's www.pharmajanes.com delivery service and select medicinal marijuana dispensaries.
Dharmanol(TM) is sold in a bottle of 8 tablets. The suggested retail price for a bottle is $25.00. Each tablet contains 5 mg. cannabidiol (CBD), 5 mg. of non-psychoactive mixed carboxylates of the primary cannabinoids, 5 mg. of mixed separated terpenes and terpenoids of cannabis/hemp, 25 mg. of organic cold-pressed hemp oil, and 25 mg. of vitamin C (ascorbic acid as a preservative).
Dharmanol Citrolene(TM) will be released shortly. This formulation combines the phyto-cannabinoid formula found in Dharmanol(TM) with a substantial dose of the terpene d-Limonene. D-Limonene is found in cannabis/hemp, but also present in the rinds of certain citrus fruits. D-Limonene has been shown to bind with the same receptors as benzodiazapines such as Valium and Xanax, producing a pronounced relaxing and anti-spasmodic effect, without the negative side effects that many attribute to the synthetic pharmaceuticals.
"We are pleased to be able to start delivering this important product to market through our distribution network of dispensaries and our related web-based delivery service www.pharmajanes.com ," said Artemus Mayor, President of SK3 Group, Inc. "These products are industry leading and will allow us to deliver the health benefits of medical marijuana to more patients who will not have to worry about feeling 'high' after their use. These products will contribute directly to our topline revenue growth."
FDA Statement The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
About SK3 SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
http://seekingalpha.com/pr/8803951-medical-greens-to-become-exclusive-distributor-of-monarch-vaporizer-pens-via-pharmajanes-com-and-through-its-affiliated-dispensaries
Medical Greens to Become Exclusive Distributor of Monarch Vaporizer Pens via PharmaJanes.com and Through Its Affiliated Dispensaries
1 comment | Wed January 29, 2014 2:00 PM|Marketwire | About: SKTO
LOS ANGELES, CA -- (Marketwired) -- 01/29/14 -- SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary Medical Greens ("the Company") is pleased to announce that it has signed an exclusive distribution agreement for the Monarch Vaporizer from Monarch Vapes, a provider of portable personal vaporizers.
The Monarch vape pen is very easy to use by simply pushing the button and inhaling. A well-measured dose of vapor is dispensed automatically. The pen itself is easily re-energized with the included USB charger and has a particularly long battery life. Each cartridge contains upwards of 100 inhalations, and is then easily replaced with another pre-filled replacement cartridge, which will be available from PharmaJanes.com and other California medical marijuana dispensaries.
The Monarch Vaporizer provides the versatility of oil while allowing users to get the benefits of E-juice, a liquid that is commonly vaporized when using an e-cigarette. It is simple, sleek, discreet, and is manufactured with uncompromising quality. Monarch's approach allows users and patients to vaporize whenever and wherever without the judgment of others.
Monarch is in discussions to team up with other companies in order to introduce vaporizable products for the medical cannabis market.
In a 2006 study, researchers at Leiden University in the Netherlands compared vaporization to smoking pure THC and found that, "Our results show that a safe and effective cannabinoid delivery system seems to be available to patients. The final pulmonal uptake of THC is comparable to the smoking of cannabis, while avoiding the respiratory disadvantages of smoking."
Through this deal, Medical Greens is capitalizing on the wave of portable personal vape pens and the growth of vaporizing in general becoming an important accessory for a growing number of Americans.
"We are pleased to sign this exclusive distribution agreement with Monarch Vapes. The e-cigarette market is growing at a tremendous rate, and it is a product with direct applicability to the medical cannabis market," said Artemus Mayor, President of SK3 Group, Inc. (SKTO) "As the size of the e-cigarette market roughly doubled each year for the past several years, we expect similar growth in the medical cannabis vaporizer market and this is an opportunity to utilize the same technology to provide safer and more effective access for cannabis patients to medicate."
----- Forwarded Message -----
From: DR <droberts2223@gmail.com>
To: Charles Apel <REDACTED>
Sent: Sunday, May 12, 2013 5:39 PM
Subject: Re: Questions Concerning Berkeley Bio-Organic Research Laboratory
Charles,
First, I want to assure you that the email is completely confidential.
I spent some time at CalTech as a post grad student working with
Richard Feynman and love California. My daughter lives in Costa Mesa
and works at Cedars-Sinai as a Nurse Practioner in the heart
transplant unit - other than being over-taxed she loves everything
about California.
I am a pretty serious investor - if you aren't serious you might as
well go to a casino and play slots.
With that said, after your email I have spent a great deal of time
researching SKTO and doing my Due Diligence.
I don't get emotionally attached to companies or stocks, I deal in facts only.
I have found out some information that has caused me some concern
about my investment. I thought I would pass this along to you because
you are involved on the scientific side and your intentions are pure.
Here is what I have found and although I have done a tremendous amount
of research I will try and be as concise as possible.
SKTO is being run by the same group that has been using SKTO as a less
than reputable ticker for the past few years – Healthcare of Today
(Henry Jan and Robert Hipple).
On 03/11/2013 SKTO issued a press release that they had acquired
Medical Greens and MG already had $12.5 million in contracts. I looked
in every state and Medical Greens was not registered as Corp or LLC
anywhere.
There was no footprint of MG - no record of taxes - nothing. In the
press release: http://medicalgreens.com/News/v/SK3-Group-Inc-Announces-Acquisition-of-Medical-
Cannabis-Company.
The MG website was created on 02/24/2013, two weeks before the press
release (although they claim to have $12.5 million in contracts).
Then on 03/22/2013 SKTO issues another press release and in two more
weeks they have another $17.5 million in contracts but there is no
information that can be verified about the now $30 million in
contracts.
Then on 04/18 iEquity registered MG as a new corporation in
California. iEquity is important because they control 60% of all of
the voting shares so they control SKTO. The men behind iEquity a
Florida Corp) is Robert Hipple and Henry Jan. I have all of this
documented.
Robert Hipple was suspended for 5 years starting in 2010 by the SEC:
http://www.sec.gov/litigation/admin/2010/34-61688.pdf
In reading the order - it seems Hipple is doing the exact same thing
behind the scenes at SKTO. I actually believe he is in violation of
the court order.
I believe the SKTO team have made misstep after misstep with their
press releases that were meant to excite investors.
Example 1, SKTO claims to have obtained 40 acres in "Southern
California to develop indoor and outdoor state-of-the-art growing
facilities for the collectives it is managing". To me this is asking
for problems under the present climate with the DEA.
Example 2. iEquity has a new site up called PharmaJanes.com,
"PharmaJanes™ allows individuals to purchase Medical Marijuana through
a website and smart phone application anywhere such a transaction is
legal in the United States." To my knowledge this isn't legal
anywhere.
Also, and this isn't pleasant but I believe it goes to motivation,
Kevin Allyn's house is in foreclosure. The company handling the
foreclosure: https://www.lpsasap.com TS #9526-3104. The address is
10517 Sarah Street, Toluca Lake, CA 91602
http://www.city-data.com/los-angeles-county/S/Sarah-Street-15.html.
The only reason I believe this to be germane to the discussion is
because Allyn might be forced due to his financial situation to become
involved with Robert Hipple.
All three of the "employees" Artemus mayor, Michael Choo and John
Burke can all be linked back to Robert Hipple with different shells.
Charles, I am cashing out on SKTO because of what has turned up in my
research. I have specific examples but didn't want to bore you with
too many details at this time.
I believe the SKTO team has targeted you because of not only your vast
knowledge on the chemical side of MMJ but your reputation as a
scholar. The men behind SKTO have no intentions of having a MMJ
company - actually they just recently changed business models because
all of the companies in the MMJ sector were doing extremely well. But
it seems the trend has passed.
Please be careful in dealing with SKTO because they want to use yours
and David Hoye's names to attract investors.
I will be more than happy to provide you with more information.
Sorry for being so long winded but I thought you should be aware of
what I have found about SKTO.
David Roberts
http://www.medicalgreens.com/docs/pdfs/Roberts-email-to-Apel.pdf
At .03 a share, this is an amazing value!
I'm telling you that I've seen con stocks and I've seen authentic upstarts. This company is growing and showing progress as much as they can.
Here are dispensaries listed from San Diego to San Francisco. I don't know who owns what, but they are there in Cali and they are selling a lot of marijuana products. Someone's making money!
http://listings.canorml.org/medical-marijuana-collectives-dispensaries-and-delivery-services-in-california/
There has been no news, negative or positive. There's no reason to sell just because there hasn't been a pr for a few days!
Geez! Relax a little and give them a chance to finish the next big step. Look how much progress has been made in the last year.
Don't be so quick to abandon ship. This company will be around for a long time and IEquity is still making business moves toward growth of the company.
This is being financed by some deep pockets and isn't just going to disappear overnight. Don't let these shorty shorts steal your shares from you. They have silver tongues but their tongues are forked!
Momentum can and will change. That's how this game is played. Zooms up and crashes down.
The officers of SKTO are not even getting paid yet. They're building the company up to a profit generating machine before they get paid.
Even as the stock is in a down mode, it must be looked at as a buying opportunity.
Stay strong because greener days are coming!
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Read more: http://www.benzinga.com/content/4154694/sktos-medical-greens-announces-start-of-distribution-of-dharmanol#ixzz2u9iy9my5
‘Making the World a Better Place’ … Girl Scout Slings Cookies To Hungry Stoners Outside S.F. Collective'
http://www.marijuana.com/news/2014/02/making-the-world-a-better-place-girl-scout-slings-cookies-to-hungry-stoners-outside-s-f-collective/
Oh how the times have changed! No loner a social pariah, medical marijuana collectives are now (apparently) a hub for the entrepreneurial sprit. In one of the more brazen displays of balls to wall capitalism, a Girl Scout Ambassador in California was noticed slinging her ”Girl Scout Cookies” (GSC) outside a San Francisco medical marijuana collective.
While the name “Girl Scout Cookies” holds a slightly different significance for many of today’s pot smokers, to Danielle Lei, 13, who set up shop in front of The Green Cross on Monday, they meant cash. Lot’s of it. According to Mashable, selling a chronic 117 boxes of GSC in approximately two hours. That’s more than a box a minute.
The number one rule of business is … Location, Location, Location.
Understanding that simple rule, Lei’s mother reached out to the dispensary in advance to ask for authorization to set up a table outside. Smelling a marketing opportunity, the D’s owners greeted Danielle and her mother with an irie smile and reportedly copped several boxes.
According to the Huffington Post, despite a similar recent story in Colorado which turned out to be a Gawker post (with a slightly humors Photoshop job), both the owner of The Green Cross dispensary and the girl’s mother confirmed the San Francisco tale of entrepreneurial spirit .
While the medical pot shops owner and their patients were thrilled to have the endorsement of a Girl Scout ambassador slinging her wares outside their collective; the question remains, what with the Girl Scouts of America think?
A representative the Huffington Post contacted the Girl Scouts of America and were told that; “the decision of where to sell cookies is ultimately up to the parents.”
“Our number one concern is the safety of girls,” said the representative. “As long as they’re following our safety guidelines, we trust our parents to make decisions for their daughters based on the communities that they live in.”
This policy seems to differ from that of the Girl Scouts of Colorado, which issued the following tweet after the earlier rumor spread:
"If you are wondering, we don't allow our Girl Scouts to sell cookies in front of marijuana shops or liquor stores/bars."
Despite the potentially controversial nature of the plan, fans on Twitter have called Lei “savvy,” “genius” and the smartest Girl Scout in the country.
http://cannabisnews.com/news/27/thread27904.shtml
...Today, Boulder, Colo., is a city of 100,000 that has three Walgreens — none of which sell marijuana — and more than 100 medical marijuana dispensaries, even before licensing commences for shops that seek to sell weed for recreational use. Major national chain stores are not yet applying to sell pot, but at the Cannabis Cup convention and on hundreds of Web sites of marijuana-related businesses, the battle against liberalizing pot laws seems lost.
“The momentum to treat marijuana as a legal drug is irreversible,” says McCaffrey, the former drug czar. He no longer accepts invitations to appear on television to debate the issue because he says the networks “only wanted a rented idiot general who didn’t understand that marijuana was harmless and filling America’s jails. The opposition has gone silent. The politicians, police, judges know this is bad policy but they don’t make a peep. So we’re going to end up with impaired surgeons and air pilots. We’re just accepting another drug of abuse.”
After half a century of advocacy, Aldrich now predicts that “marijuana’s going to be legal in the United States in 10 years. Of course, I first said that in 1967.” He laughs. But this time, he says, it’s unstoppable: “It’s taken 40 years to reach a point where our national leaders have smoked. The last three presidents have admitted it.”
If legalization spreads beyond Colorado and Washington state, it likely will be because of a confluence of forces that have gathered steam during the past decade: Big money is backing the new, aboveground marijuana industry, the Internet has altered the kind of messages that Americans hear about pot, Americans have grown more libertarian in their perspective on personal freedoms, the most anti-marijuana generation has passed on, and people across the ideological spectrum have grown frustrated with the cost, both financial and social, of decades of arrests and imprisonments.
Legalization drives are underway mainly in states facing tough budget problems. Just as casino gambling spread first among states hungry for new tax revenues, so too are hard-up states now realizing, as Stroup says, that “big money can be made and suddenly the sin doesn’t matter that much.”
The burgeoning marijuana industry has flourished on the Internet, where back channels filled with anecdotal accounts of marijuana’s medicinal benefits have fed consumer appetites for everything from seeds to growing equipment to edibles.
Angelo Capozi, 45, spent decades as a chef, even appearing on TV’s “Iron Chef America,” before starting TwoSticky.com, which makes marijuana-laced peanut butter and honey. He made the switch after experimenting with recipes on behalf of his father, a cancer patient looking for relief from pain.
Capozi believes the doorway to legal status opened as his parents’ peers began to die.
“Once that generation’s out of here, it’s going to really open up,” he says. “Within a few years, I expect to be able to put my product on a supermarket shelf with a bar code.”
The passing of the baby boomers’ parents has created the first cross-generational consensus in favor of liberalized laws, says Stroup, now 70. “We knew we were going to win demographically, eventually,” he says. “I just wasn’t sure I’d see it in my lifetime.”
The generational shift change has greatly diminished the organized opposition. Few parent groups remain active; Rusche’s National Families in Action still exists, but its founder now supports decriminalization. Rusche, 75, still believes marijuana is harmful, but she has concluded that the parents’ movement erred in failing to present alcohol and tobacco as the same sort of gateway drugs as marijuana.
“There are a whole lot of arrests that shouldn’t be happening,” Rusche says. “We don’t want to see laws unfairly applied with people of color overwhelmingly being the ones arrested.”
Her longtime ally is startled to hear of Rusche’s altered stance.
“I’m just stunned,” Carla Lowe says. “Decriminalization is just a step to legalization. What we’re seeing today is a grab for taxes and a power play by a fast-growing industry.”
Even with a diminished opposition, the path to legalization faces considerable obstacles, especially from parents who don’t want their teens to be too easily tempted by the drug, city residents who envision street corners teeming with kids getting high, and sheriffs and police chiefs who say marijuana arrests remain a powerful tool against drug abuse and other crimes.
Diane Goldstein, a retired police lieutenant in Redondo Beach, Calif., went from busting drug users to working for Law Enforcement Against Prohibition, a nonprofit group critical of “the failures of our existing drug policies.” Some ex-
colleagues tell her she’s dishonoring officers who died enforcing drug laws, but Goldstein, a Republican and a grandmother, says her audiences at Rotary clubs and Republican women’s groups increasingly support taxing and regulating marijuana.
“We’re never going to be drug-free,” says Goldstein, who says she hasn’t used pot since high school. “But we can make it less available to kids by making it legal and restricting access. And we can stop marginalizing people because they’ve been arrested for pot and can’t get student loans or jobs.”
As the rhetorical battle continues and politicians remain cautious about speaking out on marijuana, the facts on the ground are changing fast. The Cannabis Cup, an open-air marketplace the size of two football fields in the San Bernardino Valley, featured open consumption of pot-infused sodas, candies and cookies and displays of whole marijuana plants — staged with virtually no controversy.
“Generations coming up now don’t see what the big deal is,” says Brian Wansolich, 39, wearing a white coat emblazoned with the logo of his online cannabis ratings service, Leafly. “My parents still have moral problems with it, but now they see we can tax this and get states out of trouble. It’s the American way.”
Source: Washington Post (DC)
Author: Marc Fisher
Published: February 22, 2014
Copyright: 2014 Washington Post Company
Contact: letters@washpost.com
Website: http://www.washingtonpost.com/
URL: http://drugsense.org/url/mLofHjml
By the time IEquity can convert it's shares, Medicalgreens will be in a much better position as far as share price and earnings being proven.
Once analysts and investors see numbers from the successful sales started this quarter, balances will be changing in our accounts very quickly. The cash register will be singing a sweet tune.
Buy 'em while they're practically free. We see the weed wave washing over this country as we speak. Might as well ride that wave all the way in to financial security. Go SKTO!
Informative post. I learned a little tonight. Thanks, I-Glow.
It's interesting to me that here in Florida, I don't pay sales tax on my prescriptions at Walmart.
I would think that medical marijuana would not have sales tax on it even in Cali. What do you say about that, I-Glow?
Henry Jan appears to be a more than honorable man. Charitable and respectable...Here is his last 14 years of work listed...
http://www.linkedin.com/in/henryjan
Henry Jan's Experience
Founder/Chairman/CEO
FlowRising
January 2014– Present (2 months)Los Angeles/Las Vegas
FlowRising is a Los Angeles/Las Vegas-based entertainment company created to develop, produce, and distribute music, film, television, interactive media, and gaming content through its wholly-owned subsidiaries FlowRising Music, FlowRising Pictures, FlowRising Interactive, and FlowRising Gaming. FlowRising also manages the FlowRising Fund, a private investment entertainment fund.
www.flowrising.com
Founder/Executive Director
iEquity Cancer Foundation
November 2013– Present (4 months)Los Angeles
iEquity Cancer Foundation was formed to give assistance and create awareness for progressive treatments and care for diseases and medical conditions focusing primarily on cancer.
www.iequitycancerfoundation.org
Founder/Chairman/CEO
iEquity Corp
May 2012– Present (1 year 10 months)Los Angeles
iEquity Corp was formed to develop, consult, and arrange financing for various medical cannabis companies. iEquity Corp currently holds controlling interest and intellectual property in several medical cannabis companies.
www.iequitycorp.com
CEO/Chairman
World Poker Fund
January 2012– Present (2 years 2 months)International
www.worldpokerfund.com
CEO/Chairman
Mergers and Acquisitions
January 2001– Present (13 years 2 months)Domestically and Internationally
Principal to over 150 Mergers and Acquisitions aggregating over $5B in transactions.
CEO/Chairman
Healthcare of Today
Privately Held; 11-50 employees; Hospital & Health Care industry
May 2008– February 2012 (3 years 10 months)Burbank, CA
IEquity Corp is the backer of several MJ companies...
"Established in 2012, iEquity Corp was created to develop companies and projects in the medical cannabis space.
iEquity Corp currently holds controlling interest and retains intellectual properties and contracts in several medical marijuana companies and projects."
AEGY board message #83261 shows evidence of a successful delivery from Pharmajanes.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=97342943
Nice pic! That's SKTO when it finally breaks it's chains! Thnx, Swag!
It appears the shorts have lost the ability to keep SKTO down and are becoming very anxious about their losses.
They know this thing is going up and time is not on their side.
The RISK is ON, shortie, and the longer you wait, the worse it will be for your account balance!
Only good news happening for AMBS!
Shorts have picked on the wrong play with AMBS!
There has been too much progress to fall back now!
Solantey trying to pass off 3 year old article as news...
Here's where he got the $1 million bridge stuff:
Don't believe what the shorters say!
http://www.amarantus.com/press-release/pr_michael_j_fox_grant_04272010.pdf
Solantey said:
Takes some profit at the open today.
Company's Stated Purpose At the One Med Forum Means Substantial Dilution
http://www.onemedplace.com/database/list/cid/13336/
"Amarantus Therapeutics is seeking to raise a $1 million investment as a bridge to a $15 million Series A that it will use to advance its lead programs in Parkinson's and Myocardial Infarction into clinical development."
A Series A round is the name typically given to a company's first significant round of venture funding in the Silicon Valley model of startup company formation.
Now you know why they needed the increase to 1,000,000,000 shares.
This is headed much lower.
p.s. The retail investors will suffer the losses. It's just the way it happens with these "penny stock" start-ups.
Amarantus buys neurodegenerative diagnostic IP portfolio from Power3 Medical
Sunnyvale, California
Saturday, December 29, 2012, 12:00 Hrs
Amarantus BioScience, Inc., a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has purchased all the intellectual property (IP) assets from Power3 Medical Products. Power3 was in bankruptcy, giving Amarantus the ability to acquire all of Power3’s IP for the diagnosis of multiple neurodegenerative diseases and oncology for US$ 40,000.
With the acquisition of these assets, Amarantus added the following issued patents to its portfolio: 12/802,630 – Diagnosis of Parkinson’s Disease, 13/118,175 – Assays for diagnosis and therapeutics…ALS and Parkinson’s Disease, 12/069,807 – 47 Protein Biomarkers for Neurodegenerative Diseases, 12/804,868 – Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders and 13/153,669 – Diagnosis of Alzheimer’s Disease.
As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson’s, Alzheimer’s, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukaemia (CML). The Company also acquired all of the data generated by Power3 while creating its IP portfolio. All of the disease states covered by the intellectual property acquired from Power3 are related to Programmed Cell Death (Apoptosis).
“The patents, patent applications and supporting data sets acquired as part of this transaction are a tremendous addition to our intellectual property estate, and fit well into the overall diagnostics strategy Amarantus is pursuing to support our therapeutics programs,” said Gerald E Commissiong, president and CEO of Amarantus. “We are now poised to advance our diagnostic pipeline for Parkinson’s disease and Alzheimer’s disease towards commercialisation.”
In addition, Amarantus has retained the services of Dr. Essam Sheta, former CLIA Laboratory Director at Power3, to assist the Company in preparing the phase II validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
Earlier this year, Amarantus entered into an exclusive worldwide license agreement with Power3 for the Company’s NuroPro Blood Test as it relates to Parkinson’s disease diagnosis. With the acquisition of Power3’s IP, Amarantus now owns the patents underlying the license and has no further financial obligations to Power3.
http://pharmabiz.com/NewsDetails.aspx?aid=72932&sid=2
Solantey is digging up 3 year old articles and trying to pass them off as news.
Here's where he got the $1 million bridge loan stuff from...
http://www.amarantus.com/press-release/pr_michael_j_fox_grant_04272010.pdf
Solantey said:
Could easily retrace to a penny or lower.
$15,000,000 in dilutive "Series A" financing in the works. The company's stated goal.
http://www.onemedplace.com/database/list/cid/13336/
"Amarantus Therapeutics is seeking to raise a $1 million investment as a bridge to a $15 million Series A that it will use to advance its lead programs in Parkinson's and Myocardial Infarction into clinical development."
There always seems to be a new group of newbies willing to get burned on the next pump and dump.
The common folk get burned in 99% of these penny start-ups in the early years.
1,000,000,000 shares on the way. :(
p.s. Try to exit at the open. There will be no bounce today.
GLTA
All imho.
Former NFL player, Coy Wire, on Erin Burnett's CNN show tonight.
He was talking about the high incidence of brain injury in the NFL and that there will be billions of dollars of lawsuits from former players for lack of action by NFL management.
http://www.cnn.com/video/#/video/bestoftv/2013/01/10/exp-erin-brain-disease-and-the-nfl-coy-wire.cnn
MANF better than GDNF. Enough said.
Let's not forget what we have in a company like AMBS:
1. A GREAT CEO and experienced team
2. A great pipeline of treatments and medicines to come
3. An uplisting to a major exchange soon
4. A partnering or possible buyout at any time
5. Peace of mind when we go to sleep at night
Trond's World...CLSN
Wednesday, December 19, 2012
Celsion and Oncothyreon
Celsion still is a good investment thesis.
If you have not heard, Oncothyreon had a failed trial this morning and had the share price cut by more than 50%. As a disclosure, I had no position in ONTY but was in it a couple years ago for the continue at the first interim. I do have a lot of friends and colleagues who were in it, some quite heavily, and they are hurting quite a bit this morning.
Celsion has had a number of people who are bullish because of models showing the trial “is running longer than it should, thus it must be doing well.” ONTY, as numerous trials have before this, should serve as a wake-up call to these investors. Fortunately, Celsion’s Thermodox has a plethora of features that allow me to be “watchfully bullish.”
For one, the method of action (MOA) is pretty clear.
Reviewing the concept in extremely basic language, Thermodox is the chemo doxorubicin, covered by a fatty layer. That fatty layer is engineered to be attracted to the “leaky” blood vessels that are found most prominently in tumors. So after Thermodox is infused into the patient, these entities congregate around tumors. When radio-frequency ablation (RFA) occurs, burning away the cancerous tissues, that fatty layers cracks open (it has been compared to a hexagonal soccer ball) and releases the doxorubicin, bathing the tumor and surrounding tissue in the chemotherapeutic agent.
Doxorubicin does two extra things germane to this process:
Its cell-killing activity is heightened by heat. Thus it’s even more effective than normal.
It lowers the temperature of the surrounding tissue. This means heat-activated ablation is more effective, especially in the margin areas that otherwise would not be completely ablated.
Importantly, both RFA and doxorubicin are known processes and drugs, with a familiarity by doctors and the FDA.
I question the models that show the trial is “going long.” We are actually on the schedule put out by management in the prior year. Enrollment took a heck of a lot longer than anyone initially thought. And HCC is a wide-open kind of cancer, where many issues interact and no patient can be said to be “average.” The size and number of tumors, where they are located, and general health (otherwise to the cancer!) all have a lot to do with their prognosis. While generally speaking the median progression-free survival (PFS) should be around 12 months for the RFA-only group in the trial, the clinical sites are at some of the most skilled RFA-practitioners in the world. Patients who are in clinical trials tend to have better outcomes, due partially to the placebo effect, to the improved follow-up care and also simply by the desire to live as evidenced by being willing to enter a clinical trial. I will not be surprised to see PFS for the placebo arm come in higher than 12 months.
The Japanese firm Yakult partnered with Celsion a couple years ago, and before partnering you can be sure they got a peek at the preclinical and other available Thermodox data. At the beginning of 2011 Yakult elected to pay an extra couple million dollars upfront in order to receive a lower-than agreed royalty rate going forward. I cannot imagine how that can be spun as anything but positive. Philips Healthcare has partnered with us using their high-frequency ultrasound (HIFU) technology at the heating mechanism in lieu of RFA. They are paying trial costs, which is a reasonable (and bullish) commitment, also having seen private company data. I think it fair to propose that preclinical and ph1 data are reasonably strong.
The most “squishy” factor to consider is the insider buying. Several officers and directors have recently bought shares on the open market or exercised options or warrants. As a reminder, this takes real money, either straight up or as “income” defined by the IRS, and so it is coming out of these folks’ disposable income. As the old saw goes, insiders can sell for many reasons, but there is only one reason for them to buy.
Alongside that, we need to look at the company’s refusal to do a financing prior to data, and in fact their reiterated commitment NOT to do so very recently. This is pretty much unheard of, and very bullish. Let me be explicit here – the insider buying and no-raise factors are bullish but these people do NOT have much more insight into the trial than investors do. They do not have unblinded info from the interim look, they don’t get “winks and nudges” from the Data Monitoring Committee (DMC), and they cannot trade if they did know such things. But they are the closest to the data and such actions should at least be acknowledged.
In sum, I feel Celsion at a sub $300M market cap is undervalued and eminently tradable. I think the HEAT trial has a very reasonable chance of success and have a 2-month target price of $20.
Disclosure and disclaimer:
I own shares and option of Celsion at the time of this writing and while my positions may change, I have no intention of doing so within three days of this article. My own resources, risk tolerance, and personal situation have been taken into consideration for any trades mentioned and should not be used as a basis for someone else's trades. Stocks may lose value and this is not recommendation to buy or sell this particular issue.
This is presented for educational and informational purposes only, and should not be construed as personalized legal, tax, investment, or financial advice.
Posted by Trond at 9:52 AM 2 comments: Links to this post
Labels: Celsion, CLSN, Oncothyreon, ONTY, RFA, Thermodox